ABSTRACT
Background Resistant hypertension is quite prevalent and a risk factor for cardiovascular events. Patients with suspected resistant hypertension undergo more screening intensity for secondary hypertension, despite some of them being non-adherent to prescribed pharmacotherapy. The prevalence of non-adherence in this setting varies from about 5 to 80% in the published literature. Apart from the wide range, the relation between method of assessment and prevalence is not well established. Our objective was to establish the overall prevalence of non-adherence in the apparent treatment resistant hypertension population, explore causes of heterogeneity, and evaluate the effect of the method of assessment on the estimate of non-adherence.
Methods We performed a systematic review and meta-analysis. MEDLINE, EMBASE Classic+EMBASE, Cochrane, CINAHL, and Web of Science were searched for relevant articles. Details about the method of adherence assessment were extracted from each included article and grouped into direct and indirect. Pooled analysis was performed using the random effects model and heterogeneity was explored with metaregression and subgroup analyses.
Results The literature search yielded 1428 studies, of which 36 were included. The pooled prevalence of non-adherence was 35% (95% confidence interval 25 – 46 %). For indirect methods of adherence assessment, it was 25% (95% CI 15 – 39 %), whereas for direct methods of assessment, it was 44% (95% CI 32 – 57 %). Metaregression suggested gender, age, and time of publication as potential factors contributing to the heterogeneity.
Conclusions Non-adherence to pharmacotherapy is quite common in resistant hypertension, with the prevalence varying with the methods of assessment.
Brief Summary Resistant hypertension is known to be a risk factor for cardiovascular events. These patients also undergo higher screening intensity for secondary hypertension. However, not all patients with apparent treatment resistant hypertension have true resistant hypertension, with some of them being non-adherent to prescribed pharmacotherapy. This systematic review aims to establish the overall prevalence of non-adherence in the apparent treatment resistant hypertension population and assess the relative contributions of non-adherence assessed with direct and indirect measures.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
CRD42020137944
Funding Statement
No direct funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Systematic Review, no IRB approval necessary
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
gabourque{at}toh.ca, jilin016{at}uottawa.ca, mruzicka{at}toh.ca, adavis{at}toh.ca, ghundemer{at}toh.ca
Data Availability
We only use publicly available data
LIST OF ABBREVIATIONS
- ABPM
- Ambulatory Blood Pressure Monitoring
- BP
- Blood Pressure
- CHF
- Congestive Heart Failure
- CI
- Confidence Interval
- CINHAL
- Cumulative Index of Nursing and Allied Health Literature
- CKD
- Chronic Kidney Disease
- CVD
- Cerebrovascular Disease
- DBP
- Diastolic Blood Pressure
- DOT
- Directly Observed Therapy
- HR
- Heart Rate
- MARS
- Medication Adherence Report Scale
- MEMS
- Medication Event Monitoring System
- MMAS
- Morisky Medication Adherence Scale
- PDC
- Proportion of Days Covered
- PRISMA
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses
- RCTs
- Randomized Controlled Trials
- RH
- Resistant Hypertension
- SBP
- Systolic Blood Pressure
- TDM
- Therapeutic Drug Monitoring
